Clinical trial investigates vaccine to treat recurrent respiratory papillomatosis after surgery
HPV-16 E5 oncoprotein
Photo courtesy of NCI Visuals Online
Adults with recurrent respiratory papillomatosis (RRP) who have had at least two surgeries to reduce lesions in the last 12 months may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Scott M. Norberg, D.O., Assistant Research Physician in the Genitourinary Malignancies Branch, is leading a study of PRGN-2012, an experimental therapeutic vaccine for adults with RRP. RRP is a rare disorder caused by human papillomavirus (HPV). People with RRP develop small, wart-like growths (papillomas) in the upper and lower airways and lungs that can obstruct breathing and lead to respiratory complications. There is no systemic treatment for RRP. Patients require repeated surgeries to remove lesions as they grow back and spread. PRGN-2012 is an experimental therapeutic vaccine designed to create a response by the body’s immune system that will send T cells directly to cells infected with HPV. Investigators want to see if treating patients with PRGN-2012 after surgery for RRP will decrease the recurrence of lesions and thus reduce the number of complex surgeries that patients must undergo.
Clinicaltrials.gov identifier: NCT04724980
NCI Protocol ID: NCI-21-C-0013
Official Title: A Phase I Study of Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.Wed, 03/24/2021